文献速递系统性红斑狼疮

阿尼鲁单抗治疗系统性红斑狼疮:西班牙206例多中心真实世界证据及文献综述

Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review.
PubMed 文献 · RMD Open · 2026-03-19

该多中心真实世界研究纳入206例符合EULAR/ACR 2019分类标准的SLE患者,评估阿尼鲁单抗在临床实践中的有效性及安全性。结果显示疾病活动度指标、LLDAS、DORIS缓解、血清学标志物及激素减量方面均获快速持续改善,器官损伤保持稳定,安全性特征良好,与已发表观察性研究一致。

要点

  • 阿尼鲁单抗在真实世界中可快速持续改善SLE疾病活动度并实现激素减量
  • 最常见不良事件为带状疱疹、呼吸道感染和头痛,20例患者停药
  • 真实世界结果与已发表观察性研究一致,支持将阿尼鲁单抗纳入常规诊疗

核心结论

  • 在大规模真实世界队列中,阿尼鲁单抗显示出早期且持续的临床获益、良好的安全性特征及显著的激素节约效应。

研究设计与样本

  • 西班牙54个中心的多中心研究,纳入206例符合EULAR/ACR 2019分类标准的SLE患者(183例女性,平均年龄44.6±12.6岁),数据收集至2025年4月30日。
  • 同时进行了已发表观察性研究的文献综述。

主要发现

  • 阿尼鲁单抗最常见适应症为皮肤(61.7%)、肌肉骨骼(48.5%)和血液学(27.2%)表现。
  • 疾病活动度(SLEDAI-2K、SLE-DAS、PGA)、LLDAS、DORIS缓解、血清学标志物(抗双链DNA、C3/C4)及激素减量方面均观察到快速持续改善。
  • 器官损伤保持稳定,平均随访7.5±5.3个月。
  • 最常见不良事件为带状疱疹(n=5)、呼吸道感染(n=6)和头痛(n=3),20例患者停药。

关键数值与推荐

  • LLDAS和DORIS缓解作为疾病控制衡量指标被评估并显示改善。
  • SLEDAI-2K、SLE-DAS和PGA用于评估疾病活动度。

临床怎么用

  • 真实世界证据支持将阿尼鲁单抗纳入SLE常规诊疗,尤其适用于皮肤、肌肉骨骼和血液学表现为主的患者。
  • 治疗中应关注带状疱疹和呼吸道感染等不良事件。

局限性

  • 平均随访时间较短(7.5±5.3个月),长期数据有限。
  • 为观察性真实世界研究,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anifrolumab is approved for adults with moderate-to-severe active systemic lupus erythematosus (SLE) based on Randomised clinical trials (RCTs). While randomised pivotal RCTs have demonstrated their efficacy and safety, real-world evidence (RWE) remains limited. OBJECTIVES: To describe the clinical characteristics, effectiveness and safety of anifrolumab in clinical practice and to assess findings from published observational studies. METHODS: Multicentre study of patients with SLE classified according to EULAR/American College of Rheumatology (ACR) 2019. Data were collected from medical records up to 30 April 2025. Variables included demographic characteristics, clinical and serological features, prior and concomitant therapies, disease activity indices including the SLE Disease Activity Index 2000 (SLEDAI-2K), SLE Disease Activity Score (SLE-DAS) and Physician Global Assessment (PGA), damage and disease control measures including the Systemic Lupus International Collaborating Clinics/ACR Damage Index, Lupus Low Disease Activity State (LLDAS) and Definitions of Remission in SLE (DORIS) remission and the association with adverse events (AEs). A review of published observational studies was also conducted. RESULTS: We included 206 patients (183 women; mean age 44.6±12.6 years) from 54 Spanish centres. The most common indications for anifrolumab were cutaneous (61.7%), musculoskeletal (48.5%) and haematological (27.2%).A rapid and sustained improvement was observed in disease activity (SLEDAI-2K, SLE-DAS, PGA), LLDAS, DORIS remission, serological markers (anti-double-stranded DNA, C3/C4) and corticosteroid tapering. Organ damage remained stable. After a mean follow-up of 7.5±5.3 months, the most frequent AEs were herpes zoster (n= 5), respiratory infections (n= 6) and headache (n= 3). Twenty patients discontinued treatment. These results were consistent with published observational studies. CONCLUSION: In this large RWE cohort, anifrolumab demonstrated early and sustained clinical benefit, a favourable safety profile and a significant corticosteroid-sparing effect. These findings reinforce the evidence from CT and support the incorporation of anifrolumab into routine care for patients with SLE.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Calvo-Río V, Secada-Gómez C, Martín-Gutiérrez A, et al. Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review. RMD Open. 2026. PMID: 41856562. doi:10.1136/rmdopen-2025-006549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。